Sexually transmitted diseases (STDs), also referred as venereal diseases are infections that can pass from person to person during sex. These diseases are caused mainly due to bacteria, viruses, and / or parasites. Sexually transmitted diseases (STDs) often go undiagnosed because these infections usually do not exhibit visual symptoms. The global Sexually Transmitted Disease (STD ) Drug market is valued at 14300 million US$ in 2018 is expected to reach 33300 million US$ by the end of 2025, growing at a CAGR of 11.2% during 2019-2025. This report focuses on Sexually Transmitted Disease (STD ) Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Sexually Transmitted Disease (STD ) Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered: Pfizer Roche Bayer Eli Lilly Johnson & Johnson Bristol-Myers Squibb AbbVie Gilead Sciences GlaxoSmithKline Merck Segment by Regions North America Europe China Japan Segment by Type Antibiotics Antiviral Vaccines Segment by Application Hospital Clinic
Table of Contents Executive Summary 1 Sexually Transmitted Disease (STD ) Drug Market Overview 1.1 Product Overview and Scope of Sexually Transmitted Disease (STD ) Drug 1.2 Sexually Transmitted Disease (STD ) Drug Segment by Type 1.2.1 Global Sexually Transmitted Disease (STD ) Drug Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Antibiotics 1.
